Search / Trial NCT00001977

The Effect of Acetylcholine on Memory and Attention

Launched by NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) · Dec 9, 2002

Trial Information

Current as of December 26, 2024

Completed

Keywords

Alzheimer's Disease Attention Brain Functional Magnetic Resonance Imaging Physostigmine Positron Emission Tomography Working Memory

ClinConnect Summary

The goal of this research project is to determine the role of cholinergic neuromodulation in the functional organization of memory and attention in humans, using functional neuroimaging techniques. The study of human cognition with functional brain imaging in conjunction with pharmacologic probes that alter cognitive processes provides an opportunity to examine another dimension of the organization of human neural systems. In addition to identifying the anatomical structures that participate in specific cognitive functions, this approach can reveal how different neuromodulators can influenc...

Gender

ALL

Eligibility criteria

  • Three groups of subjects will be enrolled:
  • Subjects with Alzheimer's Disease (AD) 45-100 years of age;
  • Healthy controls 20-50 years of age;
  • Healthy controls 50-90 years of age.
  • No evidence of, or history of, any medical, neurological or psychiatric condition (other than dementia in the AD patient group) which may affect brain function and metabolism and/or represent a contraindication to the study; including learning disability, psychiatric condition, head trauma with loss of consciousness, seizures or other neurological conditions, alcoholism or substance abuse, hypertension, cardiovascular disease, diabetes and other endocrine diseases, malignancy.
  • No subjects with vision and/or hearing problems severe enough to interfere with testing.
  • No females with a positive pregnancy test.
  • No subjects with contraindications to magnetic resonance imaging (MRI), including pacemakers, cochlear implants, surgical clips or metal fragments in their eyes or body parts.
  • Only subjects with good health and without evidence of significant chronic disease will be accepted into the healthy control groups.
  • Only patients without evidence of significant chronic disease who meet standard clinical criteria for the diagnosis of dementia of Alzheimer's disease type will be accepted into the study in the AD group.

About National Institute Of Mental Health (Nimh)

The National Institute of Mental Health (NIMH) is a leading federal agency dedicated to advancing the understanding and treatment of mental health disorders through innovative research and clinical trials. As part of the National Institutes of Health (NIH), NIMH focuses on a broad spectrum of mental health issues, including mood disorders, anxiety disorders, schizophrenia, and developmental disorders. By fostering collaboration among researchers, clinicians, and the community, NIMH aims to translate scientific discoveries into effective interventions and improve mental health outcomes for individuals across the lifespan. Through its commitment to rigorous research methodologies and ethical standards, NIMH plays a pivotal role in shaping the future of mental health care and policy.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials